Library
Peptide records
28 peptide records. Every entry follows the same structure.
Also on Strand: Sourcing — pathways, payment, and risk — and Papers and official documents, the citations behind each record.
Status
Evidence
28 records
Semaglutide
GLP-1 metabolic medicine
Metabolic
An FDA-approved GLP-1 receptor agonist sold as finished products, including Ozempic, Wegovy, and Rybelsus. Large randomized trials support labelled uses in type 2 diabetes, chronic weight management, cardiovascular risk reduction, kidney outcomes in type 2 diabetes with CKD, and noncirrhotic MASH with moderate to advanced fibrosis on Wegovy. A compounded copy is not the labelled product.
Open recordTirzepatide
dual incretin agonist
Metabolic
A dual GIP/GLP-1 receptor agonist approved as Mounjaro for type 2 diabetes uses and as Zepbound for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Evidence comes from large SURPASS and SURMOUNT programs, including SURMOUNT-OSA. Same incretin-class cautions as other GLP-1–pathway medicines; treat it as a labelled prescription product, not a wellness peptide.
Open recordRetatrutide
triple incretin agonist
Metabolic
An investigational triple agonist. Phase 2 weight-change data exist in a peer-reviewed paper. It is not FDA-approved. Company toplines from TRIUMPH-2 and TRIUMPH-3 are not papers, and a planned BLA is not an approval. A research listing that shares the name is not the investigational product.
Open recordInsulin
glucose-regulating hormone
Metabolic
The original peptide medicine. More than a century of clinical use. It is a life-saving hormone replacement, not a performance or fat-loss tool — hypoglycemia from misuse is an emergency.
Open recordTesamorelin
HIV lipodystrophy VAT
Endocrine
Tesamorelin is an FDA-approved GHRH analog sold as finished Egrifta products for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Current labelled formulations include EGRIFTA WR (11.6 mg/vial) and EGRIFTA SV (2 mg/vial); the WR label states these products are not substitutable. Pivotal evidence is VAT reduction on CT in two Phase 3 trials, not anti-aging or general obesity use. Long-term cardiovascular safety is not established on the labels. Research-chemical listings are not the approved Egrifta products.
Open recordTeriparatide
bone-building PTH analog
Endocrine
An anabolic osteoporosis medicine with fracture-reduction data. Lifetime duration is limited on the label because of rodent osteosarcoma findings. Not a general 'healing peptide.'
Open recordBremelanotide
HSDD sexual medicine
Neuromodulatory
An FDA-approved on-demand injection for hypoactive sexual desire disorder in premenopausal women. The research-chemical name PT-141 is the same scaffold used off-label and in unregulated products — those are not the approved drug.
Open recordOxytocin
labor and bonding
Endocrine
A workhorse obstetric medicine. Social-cognition and psychiatric uses remain experimental; intranasal research is mixed and dose/delivery are unsolved.
Open recordBPC-157
tissue recovery
Regenerative
A gastric pentadecapeptide studied mainly in animals for gut, tendon, and muscle injury models. Rodent results are often positive; quality human RCTs are essentially absent. It is not an FDA-approved medicine. US compounding policy remains restrictive after nomination withdrawal from Category 2 interim policy and FDA’s proposal against 503A Bulks List inclusion at the July 2026 PCAC.
Open recordTB-500
tissue recovery
Regenerative
A research-market fragment of a naturally occurring actin-regulating peptide. Animal wound-healing data exist for Tβ4; the specific TB-500 product sold online is not a characterized human drug.
Open recordCJC-1295
GH-releasing analog
Endocrine
A research GHRH analog with a small human PK/PD literature for the DAC form. It is not an approved GH-secretagogue medicine. Tesamorelin is the approved comparator in this class.
Open recordIpamorelin
GH-releasing secretagogue
Endocrine
A clean-looking GH secretagogue on paper, with sparse modern human data. Popular in 'peptide clinic' stacks. There is no approved indication and no large efficacy program.
Open recordGHK-Cu
skin remodeling copper
Cosmetic
The peptide with the most plausible cosmetic evidence in this catalog. Still not a drug. Injectable 'GHK-Cu protocols' are a different, poorly documented practice from topical serum use.
Open recordSemax
cognitive research peptide
Neuromodulatory
A synthetic ACTH fragment analog studied mainly in Russian neurologic literature for cognitive and cerebrovascular questions. Western, independently replicated randomized trials are scarce. Treat cognition and neuroprotection claims as regionally studied, not globally settled. This record is a research compound, not an FDA-approved product.
Open recordSelank
anxiolytic research peptide
Neuromodulatory
The calmer sibling of Semax in the same development tradition. Anxiety and asthenia are the usual claims. Evidence is regional and small; it is not a validated alternative to standard anxiolytics.
Open recordEpithalon
telomere research peptide
Longevity
A longevity-circuit celebrity. Cell and animal telomere/pineal findings exist; they have not been converted into rigorous, replicated human outcome trials. 'Adds years' is marketing, not a result.
Open recordThymosin alpha-1
immune modulator
Immune
A real pharmaceutical in several countries (thymalfasin / Zadaxin) for hepatitis B and as an adjuvant in selected settings. Not FDA-approved for general 'immune optimization.' COVID-era use was exploratory.
Open recordMOTS-c
exercise mimetic
Mitochondrial
One of the more scientifically interesting mitochondrial-derived peptides. Mouse metabolic data are real. Jumping from that to a self-administered longevity drug is not.
Open recordElamipretide
Barth syndrome medicine
Mitochondrial
The labelled product is Forzinity. FDA granted accelerated approval on 19 September 2025, NDA 215244, to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. Barth syndrome is X-linked; that is disease biology, not a class of peptides. Research-chemical SS-31 is not Forzinity. Approval does not travel to a similarly named research compound, and it does not make elamipretide a general mitochondrial supplement.
Open recordCollagen peptides
connective tissue supplement
Cosmetic
A food ingredient with a better evidence trail than most 'skin peptides' sold as injectables. Effects are modest. It is not equivalent to a prescription regenerative drug.
Open recordMelanotan II
unapproved tanning peptide
Cosmetic
An unapproved tanning peptide with a concerning safety story: mole darkening, blood-pressure effects, nausea, and priapism. Afamelanotide (Scenesse) is the related approved medicine for a rare light-intolerance disease — it is not the same as gray-market MT-II.
Open recordKisspeptin-10
reproductive hormone signal
Endocrine
A legitimate endocrine research tool with human physiologic studies. Not a lifestyle peptide. Fertility-medicine development (including longer analogs) is the serious path; gray-market Kp-10 is not that path.
Open recordAOD-9604
fragment fat research
Metabolic
A failed obesity drug candidate that reappeared on the peptide market. Fragmenting GH did not deliver GH-like fat loss in adequate trials. Treat current marketing as recycling, not a new discovery.
Open recordLL-37
antimicrobial host peptide
Immune
An endogenous host-defense peptide, not a wellness supplement. Systemic or self-injected LL-37 has a plausible harm story (inflammation, cytotoxicity) that the market rarely prints.
Open recordPalopegteriparatide
Hypoparathyroidism medicine
Endocrine
The labelled product is Yorvipath (Ascendis). FDA approved it on 9 August 2024 (NDA 216490) for treatment of hypoparathyroidism in adults. It was not studied for acute post-surgical hypoparathyroidism. It is a TransCon PTH prodrug of PTH(1-34), distinct from teriparatide/Forteo, which is labelled for osteoporosis uses rather than hypoparathyroidism replacement. A research or compounded PTH listing is not Yorvipath.
Open recordNavepegritide
Achondroplasia CNP medicine
Endocrine
The labelled product is Yuviwel (Ascendis; aka TransCon CNP). FDA granted accelerated approval (content current as of 4 Mar 2026 on the FDA notice; NDA 219164 approval package dated 27 Feb 2026) to increase linear growth in pediatric patients 2 years and older with achondroplasia and open epiphyses. Approval is based on annualized growth velocity; a confirmatory final-adult-height study is required. Another labelled CNP-pathway medicine for achondroplasia is vosoritide (Voxzogo); that is a separate product and is not drafted here. This is not a general “height peptide.” Research-chemical CNP listings are not Yuviwel.
Open recordRusfertide
PV erythrocytosis medicine
Hematologic
An FDA-approved hepcidin mimetic sold as Mimrylo for treatment of erythrocytosis in adults with polycythemia vera. First-in-class therapy that targets iron availability for erythropoiesis. Research-chemical or compounded listings are not the labelled Mimrylo product.
Open recordSetmelanotide
Rare MC4R-pathway obesity
Endocrine
The labelled product is Imcivree. It is FDA-approved to reduce excess body weight and maintain that reduction in adults and children aged 4 years and older with acquired hypothalamic obesity, and in patients aged 2 years and older with Bardet-Biedl syndrome or with POMC, PCSK1, or LEPR deficiency confirmed by genetic testing. FDA expanded the hypothalamic-obesity use on 19 March 2026. The label says the product is not indicated for general (polygenic) obesity or for other genetic obesity syndromes. Unregulated melanocortin analogs are not Imcivree.
Open record